ENVB - Enveric Biosciences, Inc.

3.37
-0.280   -8.309%

Share volume: 4,481,082
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$3.65
-0.28
-0.08%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
85.16%
1 Month
68.50%
3 Months
-20.89%
6 Months
404.94%
1 Year
173.98%
2 Year
291.41%
Key data
Stock price
$3.37
P/E Ratio 
0.00
DAY RANGE
$2.99 - $3.56
EPS 
-$19.27
52 WEEK RANGE
$0.56 - $13.25
52 WEEK CHANGE
$161.24
MARKET CAP 
2.076 M
YIELD 
N/A
SHARES OUTSTANDING 
596.978 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
01-29-2025
NEXT EARNINGS DATE
05-14-2025
BETA 
0.91
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$24,947,049
AVERAGE 30 VOLUME 
$8,335,499
Company detail
CEO: Joseph Tucker
Region: US
Website: enveric.com
Employees: 20
IPO year: 2007
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Enveric Biosciences, Inc. engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 for the. treatment of cancer related distress. EV102, a cannabinoid cream for topical skin application; and EV101, a. cannabinoid and chemotherapy combination therapy.

Recent news